Dimera Logo

Inventor of the 1st Heart Drug for women

Progesterone Deficiency

*New* Chest Pain with Normal Coronary Arteries 2013 Monograph

Dimera Incorporated is pleased to announce the publication of the major cardiology reference book that addresses the unmet need of heart and cardiovascular disease in women. The title is Chest Pain with Normal Coronary Arteries, edited by Juan Carlos Kaski, Guy D. Eslick, and C. Noel Bairey-Merz, and includes 32 chapters on topics that have either never or only less thoroughly been addressed in previous medical writings.

Chest pain with angiographically normal coronary arteries is not a rare presentation, as over 50 % of patients (or even more among women) undergoing diagnostic angiography for the assessment of chest pain suggestive of coronary atherosclerosis are found not to have obstructive coronary artery disease. The newly appreciated condition-microvascular ischemia-apprears increasingly to form an important, heretofore unrecognized, main underlying cause of heart attacks and sudden heart death. Importantly, the microvascular ischemia condition can- and often does- impair the patient's quality of life and trigger serious psychological disturbances, as discussed in detail in this monograph.

Although treatment for microvascular ischemia remains problematic, management strategies are proposed in the book that can improve the patient's symptoms, quality of life and well-being. The present work specifically carries the theme creatively to new research needed to identify the different patient subgroups encompassed by this heterogeneous syndrome, to better understand its pathogenic mechanisms and devise more effective therapies.

The Dimera chapter 30 on Progesterone Deficiency represents a definition of this important previously overlooked source of cardiovascular dysfunction that is newly presented in this monograph. With the co-development of the cellular and molecular underlying etiology that predominates in women with angina pectoris with normal coronary arteries, we have contributed to a new paradigm that promises to provide effective treatment options where none previously existed. Dimera is especially pleased to have contributed one of the major chapters that opens the possibilities for new treatment platforms.

Scientists at Dimera advise that you might consider reviewing our new presentation of the Progesterone Deficiency chapter together with our DP9 (our new drug in development) page, that explains the status of this first heart drug developed for women, and provides for the essential diagnostic criteria that allow for personalization and effective medical management.